Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181546 | 0.82 | MPO (0.42) | MPOCYP11B2KDM4ECYP1A2CYP2C9 | |
| SCHEMBL1842778 | 0.81 | CYP11B2 (0.44) | MPOCYP11B2KDM4ECYP1A2CYP2C9 | |
| SCHEMBL4924021 | 0.81 | MPO (0.44) | MPOCYP11B2KDM4ECYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL18283885 | 0.72 | CYP11B2 (0.42) | MPOCYP11B2KDM4ECYP1A2CYP2C9 | |
| SCHEMBL17653924 | 0.72 | CCNE1 (0.38) | MPOCYP11B2KDM4EALDH1A1MEN1 | |
| SCHEMBL24483790 | 0.71 | CYP11B2 (0.45) | MPOCYP11B2KDM4ECYP1A2CYP2C9 | |
| SCHEMBL12121231 | 0.71 | CYP11B2 (0.45) | MPOCYP11B2KDM4ECYP1A2CYP2C9 | |
| SCHEMBL27324058 | 0.71 | LMNA (0.41) | MPOCYP11B2KDM4ECYP1A2ALDH1A1 | |
| SCHEMBL29535867 | 0.70 | SLC5A2 (0.43) | MPOCYP11B2 | |
| SCHEMBL25145864 | 0.70 | CACNA1H (0.39) | MPOCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451161-B1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | BETTATI MICHELA | 2006-02-23 | — | — | US | disclosed |
| EP-1451161-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | Merck Sharp & Dohme Limited (GB) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003048132-A1 | IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040940-A1 | Imidazopyridines pyrimidines and triazines for enhancing cognition as gaba-a-alphas 5 receoptor subtype ligands | CHRNA3, GABRA3, GABRB3 | MPO 4678/4885CYP11B2 551/4885KDM4E 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.